Skip to main content

Table 1 Characteristics of Breast Cancer Cases and Population Controls in the OFBCR

From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis

Characteristic All Cases (N = 1,115) Cases with Clinical Data (N = 967) All Controls (N = 710)
Age1    
Mean ± SD 48.6 ± 9.0 48.9 ± 9.2 48.5 ± 9.1
Menopausal Status2    
Pre- 828 (75.0%) 710 (73.7%) 497 (70.2%)
Post- 276 (25.0%) 253 (26.3%) 211 (29.8%)
Ethnicity    
White 1062 (95.3%) 899 (93.0%) 653 (95.2%)
Non-White 53 (4.7%) 68 (7.0%) 33 (4.8%)
Parity    
Nulliparous 201 (19.5%) 204 (21.5%) 106 (15.0%)
1–2 child 620 (60.2%) 562 (59.2%) 434 (61.2%)
> 3 children 209 (20.3%) 183 (19.3%) 168 (23.8%)
First-degree Family History3    
No 731 (65.6%) 618 (63.9%) 641 (90.3%)
Yes 384 (34.4%) 349 (36.1%) 69 (9.7%)
OFBCR Defined Genetic Risk Case4    
No 311 (27.9%) 281 (29.1%) NA
Yes 804 (72.1%) 686 (70.9%)  
Histology    
Infiltrating Ductal No Special Type -- 824 (90.2%) NA
Lobular   65 (7.1%)  
Other Special Type5   25 (2.7%)  
T Stage    
pT1 (<2 cm) -- 607 (64.0%) NA
pT2 (2–5 cm)   281 (29.6%)  
pT3/pT4 (>5 cm)   34 (3.6%)  
pTx (not accessible)   26 (2.7%)  
# Positive Lymph Nodes    
None -- 538 (56.6%) NA
1–3   243 (25.6%)  
≥4   113 (11.9%)  
Nx (not accessible)   56 (5.9%)  
Grade    
I (well differentiated) -- 194 (21.5%) NA
II (moderately differentiated)   351 (38.8%)  
III (poorly differentiated)   359 (39.7%)  
Lymphatic Vessel Invasion    
Negative -- 582 (66.1%) NA
Positive   299 (33.9%)  
Estrogen Receptor Status    
Negative -- 230 (24.5%) NA
Equivocal   49 (5.2%)  
Positive   659 (70.3%)  
Progesterone Receptor Status    
Negative -- 259 (27.8%) NA
Equivocal   55 (5.9%)  
Positive   618 (66.3%)  
  1. 1 age at diagnosis for cases and age at interview for controls; 2 peri-menopausal women are grouped with pre-menopausal women; 3 self-reported cancer histories of breast or ovarian cancer; 4 criteria used by the OFBCR to oversample more informative cases in order to enrich registry for genetically predisposed individuals (see methods); 5 includes medullary, tubular, cribriform, micropapillary, mucinous, metaplastic; NA, not applicable